Monthly Archives: May 2026

A Milestone in Evidence-Based Nicotine Regulation: FDA’s Environmental Assessment for Nicotine Pouches

The U.S. Food and Drug Administration’s recent programmatic environmental assessment for nicotine pouch products may represent one of the more important yet underexamined developments in modern nicotine regulation. While much public attention surrounding nicotine governance focuses on toxicology, youth access, and population health outcomes, the FDA’s latest findings introduce another increasingly relevant dimension into the…

Nicotine Summit USA 2026: Is Policy Finally Catching Up to Science?

The discussions emerging from Nicotine Summit USA 2026 suggest a growing recognition that nicotine policy may be entering a new phase, one in which regulatory systems are increasingly being challenged to reconcile long-standing public health objectives with evolving scientific evidence, consumer behavior, and market realities. As highlighted in recent reporting and commentary surrounding the Summit,…

Brazil’s 4mg Pharmaceutical Model: What ANVISA’s Direction Could Mean for Innovation, Consumers, and Latin America’s Regulatory Future

Brazil is increasingly positioning itself as one of Latin America’s most consequential regulatory bellwethers in the debate over novel nicotine products. As policymakers across the region assess how emerging nicotine categories should be governed, Brazil’s pharmaceutical-style approach, centered around strict dosage controls such as a 4mg cap, signals a distinctly cautious pathway. For GINN LatAm,…